JPRN-jRCTs031180445进行中（未招募）2 期
Phase II Trial Using Romidepsin after Gemcitabine, Dexamethasone, and Cisplatin (GDP) for Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma - NHOH-PTCL-GDPR
IWASAKI Hiromi0 个研究点目标入组 30 人开始时间: 2019年3月29日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 65age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) The patient is 65 years old or older at the time of registration.
- •2) The patient is diagnosed with peripheral T-cell lymphoma (PTCL-NOS or AITL according to the 2016 WHO classification), has previously undergone more than one treatment regimen, are not eligible for autologous and allogeneic stem-cell transplantation, and their condition has relapsed or is refractory.
- •3) The patient has a lesion that is measurable.
- •4) The patient's Eastern Cooperative Oncology Group Performance Status at the time of registration is 0-2.
- •This can be after a previous PSL dose (approx. one-week PSL administration is permissible).
- •5) The patient satisfies the following criteria and the major organ functions have been maintained.
- •5-a) The patient has a neutrophil count of 1,000/mm^3L and above.
- •5-b) The patient has a platelet count of 50,000/mm^3L and above.
- •5-c) The patient's cardiac function has an ejection fraction of over 50% (echocardiogram or myocardial scintigraphy).
- •5-d) The patient's arterial blood gas analysis shows a PaO2 of over 60 mmHg, or the percutaneous oxygen saturation measurement shows an SpO2 of over 93% (room air).
- •5-E) The patient's serum AST or ATL is less than 5 times the maximum value of the facility standard.
- •5-F) The patient's creatinine clearance is over 30 ml/min (Cockcroft-Gault).
- •6) The patient has received a notification and the content of the trial has been adequately explained to the patient by the facility investigator (assigned) using the designated consent form and explanatory materials, and the patient has provided written informed consent of voluntary participation in the trial.
排除标准
- •1) The patient has been clinically diagnosed with testis or central nervous system (brain, spinal cord, medullary cavity).
- •(An examination of the cerebrospinal fluid or an MRI of the brain is not mandatory)
- •2) The patient has uncontrolled hepatic, renal, cardiac, or pulmonary dysfunction, diabetes, or hypertension.
- •3) The patient has interstitial pneumonia or pulmonary fibrosis. (If either is determined by a plain X-ray image of the chest, the patient shall not be able to register. Mild cases indicated for the first time on a chest CT scan shall not be excluded. Patients whose lungs have been previously exposed to radiation shall be excluded, as they are at a high risk of developing interstitial pneumonia.)
- •4) The patient presents with a QTc interval that measures over 500 ms on an electrocardiogram.
- •5) The patient has a tubercular disease, herpetic simplex keratitis, systemic mycoses, or any other active infection.
- •6) The patient has had, within the past 6 months, an acute myocardial infarction, deep vein thrombosis, or a pulmonary embolism.
- •7) The patient has an active and advanced stage double cancer (synchronous double cancer and metachronous double cancer with a disease-free interval of less than 5 years. However, lesions that correspond to carcinoma in situ of the uterine cervix, the stomach, or the colon that are deemed to have been cured by local treatment are not considered as active double cancers).
- •8) The patient is HBs antigen positive, HCV antigen positive, HTLV-1 antigen positive, or HIV antigen positive. (HBs antibody and HBc antibody positive patients shall not be excluded. If HBV-DNA is detected, the patient shall be excluded. An HIV antibody test is not mandatory).
- •9) The patient has a history of severe drug hypersensitivity.
- •10) The patient lacks the ability to give consent, suffering from symptoms such as dementia.
- •11) The patient has undergone local radiotherapy less than 2 weeks prior to the trial.
- •12) The representative doctor of the facility or investigator deems the patient to be unfit to participate in the trial.
研究者
相似试验
终止
1 期
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast CancerHER2-negative Breast CancerRecurrent Breast CancerMale Breast CancerStage IV Breast CancerInflammatory Breast CancerNCT01938833Sidney Kimmel Cancer Center at Thomas Jefferson University9
已完成
1 期
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell LymphomaPeripheral T-Cell LymphomaDiffuse Large B-Cell LymphomaNCT01846390Canadian Cancer Trials Group21
进行中（未招募）
1 期
Phase IIa study on the role of Gemcitabine plus Romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.Relapsed/refractory peripheral T-cell lymphoma patients.MedDRA version: 14.1Level: HLGTClassification code 10025321Term: Lymphomas non-Hodgkin's T-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2012-001404-38-ITFONDAZIONE ITALIANA LINFOMI ONLUS20
已完成
2 期
Romidepsin Plus 3BNC117 Phase 2a StudyHuman Immunodeficiency Virus (HIV)NCT02850016Rockefeller University48
已完成
2 期
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell LymphomaPeripheral T-cell LymphomaNCT00426764Celgene131